Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2022-03-28 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Positive results from AVE's topical CBD pain study 3 pages 279.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Avecho Biotechnology Limited reporting positive results from a Phase IIa clinical study of a topical CBD gel for osteoarthritis. It includes detailed study results, investigator comments, and future plans for further trials. The content is a clinical trial result announcement rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specific announcement of clinical trial results, which is typically categorized under Regulatory Filings (RNS) in the absence of a more specific clinical trial or scientific study category. The document is not a report publication announcement since it contains substantive study data and analysis, not just a notice of report availability. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-03-28 English
Dosing begins in topical CBD pain study 2 pages 88.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Avecho Biotechnology Limited about the commencement of patient dosing for a Phase IIa clinical study of a topical CBD gel for osteoarthritis pain management. It includes details about the study, the technology used, and expected results timing. There are no financial statements, regulatory filings, or detailed financial data. The document is an update on a clinical trial progress, typical of a company announcement to investors and the market. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a presentation or a call transcript. The document is a company announcement about a clinical study milestone, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement or market update that does not fit other specific categories.
2022-02-28 English
Appendix 4E and Annual Report 31 December 2021 60 pages 1.5MB
Annual Report Classification · 100% confidence The document is titled 'Avecho Biotechnology Limited Appendix 4E Preliminary final report' and covers the financial year ended 31 December 2021. It includes detailed financial results, directors' report, auditor's independence declaration, consolidated financial statements, notes, directors' declaration, and independent auditor's report. The content is comprehensive and includes full financial statements and management discussion, consistent with an annual report. The presence of the auditor's report and detailed financial statements confirms this is the full annual report, not just an announcement or summary. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is Annual Report (10-K). FY 2021
2022-02-27 English
Appendix 4G and Corporate Governance Statement 24 pages 547.0KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by Australian listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a detailed checklist of governance principles and recommendations, indicating whether the entity has followed them and where disclosures can be found (e.g., in the corporate governance statement or on the website). It explicitly states that Appendix 4G is not a substitute for the corporate governance statement but serves as a verification tool for compliance with Listing Rule 4.10.3. The document does not contain the corporate governance statement itself, nor does it include financial data or management discussion. It is a regulatory filing required to be lodged with the ASX alongside the annual report but is a separate compliance document. Given these characteristics, the document fits best under the category of Regulatory Filings (RNS), as it is a compliance disclosure form related to governance but not the governance report itself or an annual report.
2022-02-27 English
AVE license agreement for US recreational cannabis market 3 pages 163.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Avecho Biotechnology Limited regarding a new product license and supply agreement for the US recreational cannabis market. It details the terms of the agreement, the strategic importance, and market context. There are no financial statements, quarterly or annual results, or regulatory filings such as 10-K or interim reports. The content is a corporate announcement about a business development and partnership, not a financial report or regulatory filing. It is not a call transcript, management report, or investor presentation but rather a formal announcement of a business agreement. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a general category for regulatory announcements and corporate news that do not fit other specific categories.
2022-02-01 English
December 2021 Quarterly Activities Report & Appendix 4C 8 pages 298.9KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 31 January 2022, titled 'Avecho Quarterly Activities Report and Appendix 4C' for the quarter ended 31 December 2021. It contains detailed operational updates, clinical trial progress, licensing deals, financial highlights including cash flow statements, and corporate activities for the quarter. The inclusion of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document is comprehensive, with substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but the actual quarterly report itself. Q4 2021
2022-01-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.